Newsfile Corp
03 Aug 2026, 13:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri Trial failed to achieve a statistically significant reduction in Stage III-IV cancers. — The failure of a flagship clinical trial for a core product directly undermines the company's primary value proposition and growth potential.
-0.90Berger Montague PC has filed a class action lawsuit against GRAIL alleging securities fraud and the withholding of critical trial data. — Legal action adds significant financial risk, potential settlements, and reputational damage to the company.
-0.40GRAIL shares experienced a single-day price collapse of approximately 50.55% on February 20, 2026, following the trial disclosure. — While this is a historical event, it confirms the high market sensitivity to the clinical trial's failure.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is identified as the subject of a securities fraud class action lawsuit.
The company is facing a securities fraud class action lawsuit following a 50% stock price collapse and failure of a key clinical trial.
The company is identified as the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
6h ago
